Hostname: page-component-cd9895bd7-fscjk Total loading time: 0 Render date: 2024-12-28T14:11:47.413Z Has data issue: false hasContentIssue false
  • English
  • Français

A semi-markov model for clinical trials

Published online by Cambridge University Press:  14 July 2016

George H. Weiss  and
Marvin Zelen
George H. Weiss
Affiliation:
National Cancer Institute, Bethesda, Maryland
Marvin Zelen
Affiliation:
National Cancer Institute, Bethesda, Maryland
Get access Rights & Permissions [Opens in a new window]

Abstract

This paper applies the theory of semi-Markov processes to the construction of a stochastic model for interpreting data obtained from clinical trials. The model characterizes the patient as being in one of a finite number of states at any given time with an arbitrary probability distribution to describe the length of stay in a state. Transitions between states are assumed to be chosen according to a stationary finite Markov chain.

Other attempts have been made to develop stochastic models of clinical trials. However, these have all been essentially Markovian with constant transition probabilities which implies that the distribution of time spent during a visit to a state is exponential (or geometric for discrete Markov chains). Markov models need also to assume that the transitions in the state of a patient depend only on absolute time whereas the semi-Markov model assumes that transitions depend on time relative to a patient. Thus the models are applicable to degenerative diseases (cancer, acute leukemia), while Markov models with time dependent transition probabilities are applicable to colds and epidemic diseases. In this paper the Laplace transforms are obtained for (i) probability of being in a state at time t, (ii) probability distribution to reach absorption state and (iii) the probability distribution of the first passage times to go from initial states to transient or absorbing states, transient to transient, and transient to absorbing. The model is applied to a clinical study of acute leukemia in which patients have been treated with methotrexate and 6-mercaptopurine. The agreement between the data and the model is very good.

Type
Research Papers
Information
Journal of Applied Probability , Volume 2 , Issue 2 , December 1965 , pp. 269 - 285
Copyright
Copyright © Applied Probability Trust 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

[1] Pyke, R. (1961) Markov renewal processes with finitely many states. Ann. Math. Statist. 32, 1243–1259.Google Scholar
[2] Weiss, G. H. On a semi-Markovian process with a particular application to reliability. NAVORD Report 4351. U.S. Naval Ordnance Laboratory, White Oak, Maryland.Google Scholar
[3] Fix, E. and Neyman, J. (1951) A simple stochastic model of recovery, relapse, and loss of patients. Human Biology 23, 205.Google Scholar
[4] Marshall, A. W. and Goldhamer, H. (1955) An application of Markov processes to the study of the epidemiology of mental disease. J. Amer. Statist. Assoc. 50, 99–129.Google Scholar
[5] Alling, D. (1958) The after-history of pulmonary tuberculosis. Biometrics 14, 527–547 CrossRefGoogle Scholar
[6] Taussky-Todd, O. (1954) A recurring theorem on determinants. Amer. Math. Monthly 56, 672–676.Google Scholar
[7] Feller, W. (1941) On the integral equation of renewal theory. Ann. Math. Statist. 12, 243–267.CrossRefGoogle Scholar
[8] Frei, E., et al. (1961) Studies of sequential and combination antimetabolite theory in acute leukemia: 6–Mercaptopurine and Methotrexate, Blood 18, 431–454.CrossRefGoogle Scholar
[9] Wilk, M., Gnanadeskian, R. and Huyett, M. J. (1962) Estimation of parameters of the gamma distribution using order statistics. Biometrika 49, 525–545.CrossRefGoogle Scholar